ROS damages the genetic code of the enzymes involved in transmethylation and transsulfuration and increases the degradation of GSH and the free radical hydrogen sulfide (H2S) produced
Its high affinity for IGF binding proteins allows it to act quickly at the injection site, stimulating hyperplasia and muscle cell proliferation in specific muscle groups
The injections are usually given frequently at the start of treatment
Improvements are not guaranteed, and joint pain may continue when cartilage damage, inflammation, or another structural condition is present
Human research remains limited
Introducing pills removes significant barriers to GLP-1 adoption, such as cost, needle discomfort, pharmacy logistics and manufacturing supply issues